Importance of thorough investigation of resistant hypertension before renal denervation: Should compliance to treatment be evaluated systematically?

Journal of Human Hypertension

Volumn 28, Issue 11, 2014, Pages 684-688

  Rosa, J ^a,b   Zelinka, T ^a   Petrak O ^a   Strauch B ^a   Somloova Z ^a   Indra, T ^a   Holaj, R ^a   Curila K ^b   Tousek P ^b   Senitko M ^c   Widimsky P ^b   Widimsky Jr J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

compliance adherence to treatment; renal denervation; resistant hypertension

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; BETAXOLOL; BISOPROLOL; CANRENOIC ACID; DOXAZOSIN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LOSARTAN; METOPROLOL; RAMIPRILAT; TELMISARTAN; VERAPAMIL;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; DISEASE SEVERITY; DRUG BLOOD LEVEL; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERTENSION; KIDNEY DENERVATION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; RESISTANT HYPERTENSION; TREATMENT INDICATION; TREATMENT REFUSAL; AGED; AUTONOMIC DENERVATION; BLOOD PRESSURE; CZECH REPUBLIC; DRUG EFFECTS; DRUG MONITORING; DRUG RESISTANCE; INNERVATION; KIDNEY; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PATHOPHYSIOLOGY; PATIENT REFERRAL; PATIENT SELECTION; PREDICTIVE VALUE; PROCEDURES; RETROSPECTIVE STUDY; UNIVERSITY HOSPITAL;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; AUTONOMIC DENERVATION; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CZECH REPUBLIC; DRUG MONITORING; DRUG RESISTANCE; ELIGIBILITY DETERMINATION; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; HYPERTENSION; KIDNEY; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES;

EID: 84926148253     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2014.3     Document Type: Article

References (23)

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360(9349): 1903-1913.
2. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335(8692): 765-774.
3. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34(28): 2159-2219.
4. Carey RM. Resistant hypertension. Hypertension 2013; 61(4): 746-750.
5. Savard S, Frank M, Bobrie G, Plouin PF, Sapoval M, Azizi M. Eligibility for renal denervation in patients with resistant hypertension: when enthusiasm meets reality in real-life patients. J Am Coll Cardiol 2012; 60(23): 2422-2424.
6. Verloop WL, Vink EE, Voskuil M, Vonken EJ, Rookmaaker MB, Bots ML et al. Eligibility for percutaneous renal denervation: the importance of a systematic screening. J Hypertens 2013; 31(8): 1662-1668.
7. Fadl Elmula FE, Hoffmann P, Fossum E, Brekke M, Gjonnaess E, Hjornholm U et al. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension 2013; 62(3): 526-532.
8. Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension 2013; 62(2): 218-225.
9. Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M. Difficult-to-control arterial hypertension or uncooperative patients The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res 2011; 34(1): 87-90.
10. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H et al. Resistant hypertension Assessment of adherence by toxicological urine analysis. J Hypertens 2013; 31(4): 766-774.
11. Strauch B, Petrák O, Zelinka T, Rosa J, Somloóvá Z, Indra T et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens 2013; 31(12): 2455-2461.
12. Charles-University, (Czech-Republic). Renal Denervation in Refractory Hypertension (PRAGUE-15). In: Clinical Trials.gov [Internet]; Bethesda (MD): National Library of Medicine (US). 2000-[cited 2012 March 19]. Available from: http://clinicaltrials. gov/show/NCT01560312NLM Identifier: NCT01560312, 2012.
13. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93(9): 3266-3281.
14. Gonzalez O, Iriarte G, Rico E, Ferreiros N, Maguregui MI, Alonso RM et al. LC-MS/MS method for the determination of several drugs used in combined cardiovascular therapy in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878(28): 2685-2692.
15. Chytil L, S trauch B, Cvacka J, Maresová V, Widimský Jr J, Holaj R et al. Determination of doxazosin and verapamil in human serum by fast LC-MS/MS: application to document non-compliance of patients. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878(30): 3167-3173.
16. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376(9756): 1903-1909.
17. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57(5): 911-917.
18. Brinkmann J, Heusser K, Schmidt BM, Menne J, Klein G, Bauersachs J et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension 2012; 60(6): 1485-1490.
19. Persu A, Azizi M, Burnier M, Staessen JA. Residual effect of renal denervation in patients with truly resistant hypertension. Hypertension 2013; 62(3): 450-452.
20. Persu A, Jin Y, Azizi M, Baelen M, Vö lz S, Elvan A et al. Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens 2014; 28(3): 150-156.
21. Mahfoud F, Luscher TF, Andersson B, Baumgartner I, Cifkova R, Dimario C et al. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J 2013; 34(28): 2149-2157.
22. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K et al. ESH position paper: renal denervation-an interventional therapy of resistant hypertension. J Hypertens 2012; 30(5): 837-841.
23. Witkowski A, Prejbisz A, Florczak E, Kadziela J, Sliwinski P, Bielen P et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58(4): 559-565.